POLPHARMA BIOLOGICS S.A.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 1935-01-01
- Employees
- 501
- Market Cap
- -
Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®
Phase 3
Recruiting
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: Intravenous (IV) infusions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Polpharma Biologics S.A.
- Target Recruit Count
- 750
- Registration Number
- NCT05771155
- Locations
- 🇬🇪
Todua Clinic LLC, Tbilisi, Georgia
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®
Phase 3
Completed
- Conditions
- Relapsing-Remitting Multiple Sclerosis (RRMS)
- Interventions
- Biological: Intravenous (IV) infusions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Polpharma Biologics S.A.
- Target Recruit Count
- 265
- Registration Number
- NCT04115488
- Locations
- 🇧🇾
Republican Research and Development Center for Neurology and Neurosurgery, Minsk, Belarus
🇧🇾Minsk City Clinical Hospital #5, Minsk, Belarus
🇧🇾Minsk Scientific and Practical Center of Surgery, Transplantology and Hematology, Minsk, Belarus
© Copyright 2025. All Rights Reserved by MedPath